Claim Missing Document
Check
Articles

Found 4 Documents
Search

Estimated Glomerular Filtration Rate (eGFR) as a Predictor of 1-Month Clinical Outcome in First-Ever Acute Ischemic Stroke Patients Billi; Akbar, Muhammad; David Gunawan Umbas; Hamid, Firdaus; Bintang, Andi Kurnia; Lotisna, Mimi
Journal of Society Medicine Vol. 2 No. 12 (2023): December
Publisher : CoinReads Media Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47353/jsocmed.v2i12.110

Abstract

Introduction: Renal dysfunction is a new risk factor that is thought to influence the clinical outcome of acute ischemic stroke. In this case, the estimated glomerular filtration rate (eGFR) value is used as an approach to assess kidney function status in acute ischemic stroke patients. This study aims to find the relationship between eGFR and clinical outcomes of acute ischemic stroke. Method: 70 samples were obtained according to inclusion criteria. eGFR is calculated within first week of stroke onset using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. A normality test was carried out on the data, then determined the correlation and compared eGFR with good [modified Rankin Scale (mRS) 0-2] and poor (mRS 3-6) clinical outcomes on the 30th day. Results: In this study, the average age of the sample was 61.37 years. The largest population was in the 45-59 mL/min/1.73 m2 eGFR group (38,6%). The mean eGFR (p<0.001) for all samples, good, and bad outcome groups was respectively 59.90 ± 21.09, 79.79 ± 19.21, and 52.49 ± 16.57. In this study the poor outcome group had a lower mean eGFR than the good outcome group (52.49 mL/min/1.73 m2 vs 79.79 mL/min/1.73 m2), with a cut-off value of 62 mL/min/1.73 m2 (sensitivity 80.39%, specificity 84.21%) tended to have worse clinical outcomes. Conclusion: Based on the results of this study, eGFR has a relationship with clinical outcomes (p<0.001) and can objectively predict clinical outcomes on the 30th day of acute ischemic stroke.
Rabies: Diagnostic, Treatment, and Prevention Bintang, Andi Kurnia; Basri, Muhammad Iqbal; Lotisna, Mimi; Carrey, Michael
Nusantara Medical Science Journal Volume 8 Issue 2, July - December 2023
Publisher : Faculty of Medicine, Hasanuddin University.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/nmsj.vi.27671

Abstract

Rabies is a neurological disease with fatal impacts because it has a high mortality rate. Animals, primarily dogs, mediate the spread of rabies. Clinical findings of rabies are divided into two categories: classic rabies (furious type) and paralytic type. Furious rabies has many cardinal features, such as fluctuating consciousness, aerophobia or hydrophobia, inspiratory spasm, and autonomic dysfunction. Ascending paralysis with a lower motor neuron lesion is the initial sign of paralytic rabies. The rabies virus invades and lives in neurons. It is virulent. Besides clinical findings, the diagnostic approach can involve radiology, microbiology, and histopathology. There are not only symptomatic treatments for rabies patients but also vaccines, immunoglobulin, and antivirals to decrease the progressivity of the disease. Vaccination programs and animal control have become essential in reducing rabies cases in Indonesia.
Blood Urea Nitrogen-Serum Albumin Ratio As a Predictor of Clinical Outcome in Acute Ischemic Stroke Suseno, Endy; Akbar, Muhammad; Bintang, Andi Kurnia; Soraya, Gita Vita; Lotisna, Mimi; Sompa, Andi Weri
Jurnal Ilmiah Kesehatan (JIKA) Vol. 6 No. 1 (2024): Volume 6 Nomor 1 April 2024
Publisher : Sarana Ilmu Indonesia (salnesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36590/jika.v6i1.573

Abstract

Stroke is a global health issue with high morbidity and fatality rates. Treatment decisions for ischemic stroke rely on clinical outcome prediction. The NIHSS score is commonly used to predict the AIS's clinical outcomes. However, its use is hindered by its complexity, which requires the assessment of many variables. Therefore, there is an urgent need to develop a simpler yet still effective evaluation tool in assessing the AIS’s clinical outcome. The study aimed to predict AIS outcomes using the blood urea nitrogen to albumin serum ratio (RBA). This study was a prospective cohort study design, with subjects being first-time AIS patients hospitalized at RSUP Dr. Wahidin Sudirohusodo and several hospitals in Makassar from December 2022–April 2023. Demographic and clinical data were collected, assessing RBA and comparing it according to the good (mRS 0-2) and poor (mRS 3-6) outcome groups. RBA performance was assessed by receiver operating characteristic curve (ROC) analysis to assess the AIS's clinical outcome. The study's findings on 62 participants meeting the criteria revealed a significant association between RBA and the AIS's clinical outcome (p-value=0,0004). The mean RBA differed significantly between the good and poor AIS outcome groups (p-value =0,006). In the ROC analysis, the area under the curve (AUC) was 0,75 with an optimal cut-off value was 2,05, yielding a sensitivity of 41,67%, a specificity of 98%, and a likelihood ratio of 20,83 (p-value=0,007). In conclusion, RBA can be used as a simple and objective tool to determine the clinical outcome predictors of AIS.
Comparison of Giving Mecobalamin Supplements to Improve the Severity of Painful Diabetic Neuropathy Irsyadat, Andi Muhammad; Aulina, Susi; Goysal, Yudy; Zainuddin, Andi Alfian; Lotisna, Mimi; Amran, Muhammad Yunus
Jurnal Ilmiah Kesehatan (JIKA) Vol. 6 No. 3 (2024): Volume 6 Nomor 3 Desember 2024
Publisher : Sarana Ilmu Indonesia (salnesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36590/jika.v6i3.874

Abstract

Diabetic Painful Neuropathy (DPN) is caused by the progressive loss of nerve fibers due to hyperglycemia, oxidative stress, andhomocysteinemia. Mecobalamin supplementation has shown potential in improving peripheral neuropathy symptoms by enhancing nerve conduction and alleviating neuropathic pain. However, its efficacy data remains limited. This research to investigated the effect of mecobalamin supplementation on the severity of Painful Diabetic Neuropathy in type 2 diabetes mellitus patients. This research is a non-randomized clinical trial, 16 patients were given 500 ?g of intramuscular Mecobalamin 8 times over 30 days (n=8) and 5 times over 10 days (n=8). Subjects underwent measurements VAS, TSS, BDNC and ENMG before and after intervention. VAS (p-value=0,022), TSS (p-value=0,020) and BDC (p-value=0,003) was significant improved in 8 times administration group. VAS (p-value=0,045) dan BDC (p-value=0,014) was significant improved in 5 times administration group, where TSS improved but not significant. The 8 times administration group was better compared to the 5 times administration group in improvement of VAS (p-value=0,016). Based on this research, The addition of mecobalamin 8 times and over 5 times in the management of Diabetic Neuropathic Pain can be useful in reducing neuropathic pain.